Principal Financial Group Inc Arcus Biosciences, Inc. Transaction History

Principal Financial Group Inc

$176 Billion
Q2 2025

A detailed history of Principal Financial Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 336,225 shares of RCUS stock, worth $6.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

336,225

Previous 334,981 0.37%

Holding current value

$6.79 Million

Previous $2.63 Million 4.07%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	BUY	$6.87 - $10.03 $8,546 - $12,477	1,244 Added 0.37%	336,225 $2.74 Million
Q1 2025 Apr 28, 2025	BUY	$7.85 - $15.24 $560,992 - $1.09 Million	71,464 Added 27.12%	334,981 $2.63 Million
Q4 2024 Jan 31, 2025	BUY	$14.28 - $18.44 $3.76 Million - $4.86 Million	263,517 New	263,517 $3.92 Million
Q3 2024 Oct 31, 2024	SELL	$13.69 - $18.01 $257,057 - $338,173	-18,777 Reduced 6.84%	255,611 $3.91 Million
Q2 2024 Jul 29, 2024	SELL	$14.59 - $18.48 $227,268 - $287,862	-15,577 Reduced 5.37%	274,388 $4.18 Million
Q1 2024 Apr 29, 2024	SELL	$14.83 - $20.18 $635,450 - $864,692	-42,849 Reduced 12.87%	289,965 $5.47 Million
Q4 2023 Feb 07, 2024	BUY	$13.43 - $19.63 $45,285 - $66,192	3,372 Added 1.02%	332,814 $6.36 Million
Q3 2023 Nov 02, 2023	BUY	$17.62 - $23.54 $23,117 - $30,884	1,312 Added 0.4%	329,442 $5.91 Million
Q2 2023 Aug 07, 2023	BUY	$16.97 - $22.03 $57,528 - $74,681	3,390 Added 1.04%	328,130 $6.66 Million
Q1 2023 May 09, 2023	SELL	$15.96 - $23.15 $68,101 - $98,781	-4,267 Reduced 1.3%	324,740 $5.92 Million
Q4 2022 Feb 09, 2023	SELL	$19.7 - $35.71 $240,320 - $435,626	-12,199 Reduced 3.58%	329,007 $6.8 Million
Q3 2022 Nov 09, 2022	BUY	$23.23 - $30.07 $219,035 - $283,530	9,429 Added 2.84%	341,206 $8.93 Million
Q2 2022 Aug 10, 2022	BUY	$17.23 - $37.73 $5.57 Million - $12.2 Million	323,465 Added 3891.54%	331,777 $8.41 Million
Q1 2022 May 09, 2022	SELL	$28.92 - $41.83 $7,750 - $11,210	-268 Reduced 3.12%	8,312 $262,000
Q4 2021 Feb 09, 2022	SELL	$31.38 - $48.47 $172,558 - $266,536	-5,499 Reduced 39.06%	8,580 $347,000
Q3 2021 Nov 09, 2021	SELL	$26.93 - $37.68 $61,481 - $86,023	-2,283 Reduced 13.95%	14,079 $491,000
Q2 2021 Aug 10, 2021	SELL	$22.75 - $35.77 $160,433 - $252,250	-7,052 Reduced 30.12%	16,362 $449,000
Q1 2021 May 10, 2021	SELL	$26.16 - $41.39 $17,422 - $27,565	-666 Reduced 2.77%	23,414 $657,000
Q4 2020 Feb 08, 2021	BUY	$17.0 - $32.36 $409,360 - $779,228	24,080 New	24,080 $625,000

Others Institutions Holding RCUS

# of Institutions

211

Shares Held

67M

Call Options Held

3.18M

Put Options Held

167K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.46B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Arcus Biosciences, Inc. Transaction History